Potential health hazard โ use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
Diclofenac Sodium and Misoprostol Delayed Release Tablets 75 mg/0.2 mg Recalled by Exela Pharma Sciences LLC Due to Labeling: Label Mix-Up: bottle labeled as Diclofenac Sodium...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Exela Pharma Sciences LLC directly.
Affected Products
Diclofenac Sodium and Misoprostol Delayed Release Tablets 75 mg/0.2 mg, 60-count bottle, Rx Only, Manufactured by: Cipla Ltd., India; For: EAGLE PHARMACEUTICALS, INC., Woodcliff Lake, NJ 07677 USA, NDC 42367-111-06.
Quantity: 5256 bottles
Why Was This Recalled?
Labeling: Label Mix-Up: bottle labeled as Diclofenac Sodium and Misoprostol 75 mg/0.2 mg contained Diclofenac Sodium and Misoprostol 50 mg/0.2 mg tablets.
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About Exela Pharma Sciences LLC
Exela Pharma Sciences LLC has 12 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc ยท March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. ยท March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC ยท February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC ยท February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC ยท February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report